The Retina: A Different Perspective into Alzheimer’s Disease Screening
DOI:
https://doi.org/10.47611/jsrhs.v12i1.4396Keywords:
Alzheimer's disease, Neuroscience, Clinical Diagnosis and Monitoring, OphthalmologyAbstract
The field of identifying retinal biomarkers of Alzheimer’s Disease has seen tremendous growth in recent years. The retina has great potential for being used in screening for Alzheimer’s disease (AD); it is the only part of the CNS not shielded by bone, and AD patients have several visual complaints. A number of major biomarkers in the retina have been found, including retinal nerve fiber layer (RNFL) thinning, retinovascular changes, pericyte loss and blood-retinal barrier (BRB) weakening, β-Amyloid (Aβ) deposits, Hyperphosphorylated tau and neurofibrillary tangles (NFTs), and gliosis/inflammation. All of these parallel brain biomarkers. Furthermore, new ocular biomarkers have been found (the efficacy of which is not yet fully proven) - Aβ in the lens, choroid thinning, and visual symptoms. Amyloid biomarkers probably have the most potential among these for screening; however, a multivariable model will be more effective. In the future, the Atlas of Retinal Imaging in Alzheimer’s Study (ARIAS) study, which has already commenced, will search for a wide range of retinal biomarkers in many patients in varying stages of AD and risk levels of AD; it will also explore the interrelationships between those biomarkers to find a potential multivariate screening test for AD. Also, tear fluid could be a potential future biomarker that will be relatively easy to screen. Overall, this field has made great strides in recent years, and has great potential for groundbreaking advances in the near future. The promise of course is to enable simple, inexpensive, widespread and regular screening for AD using retinal biomarkers.
Downloads
References or Bibliography
Jack, C. R., Trojanowski, J. Q., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Jagust, W. J., & Knopman, D. S. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. https://pubmed.ncbi.nlm.nih.gov/20083042/
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo-Hamaoui, M. (2020, August 10). Alzheimer's Retinopathy: Seeing Disease in the Eyes. Frontiers. Retrieved February 27, 2023, from http://www.frontiersin.org/articles/10.3389/fnins.2020.00921/full
Lim, J. K. H., Li, Q.-X., He, Z., Vingrys, A. J., Wong, V. H. Y., Currier, N., Mullen, J., Bui, B. V., & Nguyen, C. T. O. (2016, November 3). The Eye as a Biomarker for Alzheimer's Disease. Frontiers. Retrieved February 27, 2023, from http://www.frontiersin.org/articles/10.3389/fnins.2016.00536/full
Berisha, F., Feke, G. T., Trempe, C., & McMeel, J. W. (2007, June). (PDF) Retinal Abnormalities in Early Alzheimer's Disease. ResearchGate. Retrieved February 27, 2023, from https://www.researchgate.net/publication/6369508_Retinal_Abnormalities_in_Early_Alzheimer's_Disease
Tian, J., Smith, G., Guo, H., Liu, B., Pan, Z., Wang, Z., Xiong, S., & Fang, R. (2021, January 8). Modular Machine Learning for Alzheimer's Disease Classification from Retinal Vasculature. Nature News. Retrieved February 27, 2023, from https://www.nature.com/articles/s41598-020-80312-2
Armstrong, R. A. (2010, November 18). Alzheimer's Disease and the Eye. Journal of Optometry. Retrieved February 27, 2023, from http://www.sciencedirect.com/science/article/pii/S1888429609700329
Dehabadi, M., Davis, B., Wong, T., & Cordeiro, M. (2014, August 6). Retinal Manifestations of Alzheimer's Disease.: Semantic scholar. Neurodegenerative disease management. Retrieved February 27, 2023, from http://www.semanticscholar.org/paper/Retinal-manifestations-of-Alzheimer's-disease.-Dehabadi-Davis/113cdc5a841f26a766ed842b545ad720f98f74d2
Alber, J., Arthur, E., Thompson, L. I., Goldfarb, D., Fernandez, B. M., Salloway, S. P., Sinoff, S., & Snyder, P. J. (2020, July 27). The Atlas of Retinal Imaging in Alzheimer's Study (ARIAS): Study Design and Objectives. ALZ. Retrieved February 27, 2023, from alz.confex.com/alz/20amsterdam/meetingapp.cgi/Paper/45325
Koronyo Y., Biggs D., Barron E., Boyer DS., Pearlman JA., Au WJ., Kile SJ., Blanco A., Fuchs DT., Ashfaq A., Frautschy S., Cole GM., Miller CA., Hinton DR., Verdooner SR., Black KL., & Koronyo-Hamaoui M. (2017 Aug 17). Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. Retrieved February 27, 2023, from https://www.alzforum.org/papers/retinal-amyloid-pathology-and-proof-concept-imaging-trial-alzheimers-disease.
Hong Z., Zaixing Y., Xin T., Lei C., Sangyun L., Tien H., Cuicui G., & Ruhong Z. ( 2019 10 (9), 4051-4060). Lanosterol Disrupts the Aggregation of Amyloid-β Peptides. ACS Chemical Neuroscience. DOI: 10.1021/acschemneuro.9b00285
Kalló G, Emri M, Varga Z, Ujhelyi B, Tőzsér J, Csutak A, Csősz É. (2016 Jun 21;11(6):e0158000). Changes in the Chemical Barrier Composition of Tears in Alzheimer's Disease Reveal Potential Tear Diagnostic Biomarkers. PLoS One.. doi: 10.1371/journal.pone.0158000.
Yoon S., Grewal D., Thompson A., Polascik B., Dunn C., Burke J., Fekrat S. (Volume 3, Issue 6, 489-499, June 2019). Retinal Microvascular and Neurodegenerative Changes in Alzheimer’s Disease and Mild Cognitive Impairment Compared with Control Participants. Ophthalmology Retina. doi: https://doi.org/10.1016/j.oret.2019.02.002
Król-Grzymała A.,Sienkiewicz-Szłapka E., Fiedorowicz E.,Rozmus D.,Cieślińska A. & Grzybowski A. (23(17), 10123, Sept 2022). Tear Biomarkers in Alzheimer’s and Parkinson’s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). Int J Mol Sci.. doi: https://doi.org/10.3390/ijms231710123
Koronyo, Y., Rentsendorj, A., Mirzaei, N. et al. (145, 409–438, 2023). Retinal pathological features and proteome signatures of Alzheimer’s disease. Acta Neuropathol . https://doi.org/10.1007/s00401-023-02548-2
Published
How to Cite
Issue
Section
Copyright (c) 2023 Advaith Avadhanam; Ally Kim
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
